Add BrightSurf on Google Email

Virtual environment education reduces anxiety prior to radiation therapy

A pilot study conducted by Thomas Jefferson University found that a virtual environment education program significantly reduced anxiety and increased comprehension in patients receiving radiation therapy. The program used simulated environments to teach patients about their treatment, resulting in improved confidence and satisfaction.

SourceThomas Jefferson University·JournalJournal of Radiation Oncology·DateMar 23, 2017

Radiotherapy risks are much higher for smokers

A new study funded by Cancer Research UK finds that smokers treated for breast cancer have significantly higher risks of developing lung cancer or heart attacks due to radiotherapy. The long-term risk of death from these conditions is around 5% for smokers, compared to 0.5% for non-smokers.

SourceCancer Research UK·JournalJournal of Clinical Oncology·DateMar 20, 2017

FDG PET/CT found useful in certain lung cancer patients

A recent study published in the American Journal of Roentgenology found that FDG PET/CT is a valuable imaging tool for treating lung cancer patients, especially when clinical suspicion or evidence of disease recurrence or metastasis is present. However, its routine use without clinical suspicion should be discouraged until its value fo...

SourceAmerican Roentgen Ray Society·JournalAmerican Journal of Roentgenology·DateMar 1, 2017

Radiotherapy for invasive breast cancer increases the risk of second primary lung cancer

A new study has found that radiotherapy for invasive breast cancer increases the risk of developing second primary lung cancer. The research, conducted in Taiwan, involved analyzing data from over 986,000 patients with breast cancer between 2000 and 2010. The results showed a significant increase in lung cancer incidence among women wh...

SourceInternational Association for the Study of Lung Cancer·JournalJournal of Thoracic Oncology·DateFeb 15, 2017

Radiation therapy continues to be gold standard to palliate painful bone metastases

The updated clinical guideline from the American Society for Radiation Oncology (ASTRO) underscores the safety and effectiveness of palliative radiation therapy (RT) for treating painful bone metastases. The guideline recommends optimal RT dosing schedules, including options for re-treatment, to provide pain relief, with a single 8-Gy ...

SourceAmerican Society for Radiation Oncology·JournalPractical Radiation Oncology·DateFeb 14, 2017

New treatment regimen extends life for some men with recurrent prostate cancer, study finds

A new treatment regimen combining hormonal therapy with radiation treatment significantly improves the average long-term survival of men with recurrent prostate cancer who have had their prostate gland removed. The study found that this regimen also reduces the frequency of spread of the cancer, improving patient outcomes.

SourceCedars-Sinai Medical Center·JournalNew England Journal of Medicine·DateFeb 1, 2017

Adding antiandrogen to radiation therapy improves survival in recurrent prostate cancer

A study by the NRG Oncology Radiation Therapy Oncology Group found that adding antiandrogen therapy to radiation therapy can reduce the incidence of metastasis, death from prostate cancer, and overall deaths in patients with recurrent prostate cancer. The study showed a significant improvement in survival rates for patients treated wit...

SourceMassachusetts General Hospital·JournalNew England Journal of Medicine·DateFeb 1, 2017

Updated ASTRO guideline expands pool of suitable candidates for APBI

The updated guideline suggests that more breast cancer patients can benefit from accelerated partial breast irradiation (APBI), including younger patients and those with low-risk ductal carcinoma in situ (DCIS). The guideline provides direction for the use of intraoperative radiation therapy (IORT) for early-stage breast cancer patients.

SourceAmerican Society for Radiation Oncology·JournalPractical Radiation Oncology·DateNov 17, 2016

Long-term experience supports efficacy and safety of PRRT for treating neuroendocrine tumors

Long-term clinical data supports the efficacy of PRRT in treating neuroendocrine tumors, improving tumor response rates and progression-free survival. To minimize toxicity, steps such as timing of therapy, patient selection criteria, dose optimization, and adequate monitoring can be taken.

SourceMary Ann Liebert, Inc./Genetic Engineering News·JournalCancer Biotherapy and Radiopharmaceuticals·DateOct 14, 2016

The Lancet: Whole brain radiotherapy offers little benefit to people whose lung cancer has spread to the brain, despite its widespread use

Researchers found that whole brain radiotherapy had no beneficial effect on survival or quality of life compared to best supportive care and steroids. The trial included 538 patients with non-small cell lung cancer who had spread to the brain, and showed that WBRT did not extend survival or improve quality of life.

SourceThe Lancet·JournalThe Lancet·DateSep 4, 2016

New DCIS consensus guideline could curb unnecessary breast surgery and reduce health system costs

The new guideline establishes a two millimeter margin as the standard for adequate margins in DCIS treated with whole breast radiation therapy, potentially reducing re-excision rates and improving cosmetic outcomes. This recommendation is supported by evidence and aims to improve quality of care and patient outcomes.

SourceAmerican Society for Radiation Oncology·JournalAnnals of Surgical Oncology·DateAug 15, 2016

New ASTRO clinical practice statement updates treatment standard for rectal cancer

The American Society for Radiation Oncology has updated its treatment standard for rectal cancer, recommending a more customized approach that may reduce treatment side effects. The new guideline suggests alternatives to the traditional tri-modal approach, including short-course radiation therapy and non-operative management.

SourceAmerican Society for Radiation Oncology·JournalPractical Radiation Oncology·DateJul 21, 2016

Radiotherapy more effective than chemotherapy for early stage II testicular cancer

A large study of 2,437 patients with stage II testicular seminoma found that radiation therapy was associated with better outcomes compared to chemotherapy, particularly in stage IIa disease. The study's findings support the recommendation for radiotherapy as the preferred treatment option for early-stage II testicular cancer.

Demand for radiotherapy will rise substantially over next 10 years

The demand for radiotherapy is expected to increase by 16% between 2012 and 2025, with prostate cancer cases projected to rise by 24%. This is due to an aging population in Europe, with four million new cancer patients expected in 2025. The study's authors aim to help policymakers plan for increased radiotherapy services.

SourceEuropean Society for Radiotherapy and Oncology (ESTRO)·JournalRadiotherapy and Oncology·DateApr 18, 2016